Zacks Investment Research·Jun 25, 2026
Doximity (DOCS) Sees a More Significant Dip Than Broader Market: Some Facts to KnowDoximity (DOCS) concluded the recent trading session at $19.85, signifying a -4.7% move from its prior day's close.
Doximity, Inc.(DOCS)Earnings, Financials & Key Ratios
DOCS•NYSE
$22.86
23.3× P/E·Price updated Jul 6, 2026
SectorHealthcareIndustryHealthcare ITSub-IndustryHealthcare Communications, Workforce and Supply Chain
AboutDoximity, Inc. operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers. It primarily serves pharmaceutical manufacturers and healthcare systems. The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.Show more
- Revenue$645M+13.1%
- EBITDA$215M-9.9%
- Net Income$196M-12.2%
- EPS (Diluted)0.98-11.7%
- Gross Margin89.09%-1.2%
- EBITDA Margin33.33%-20.3%
- Operating Margin33.33%-16.5%
- Net Margin30.4%-22.3%
- ROE19.28%-14.3%
DOCS Price & Volume
Doximity, Inc. (DOCS) stock price & volume — 10-year historical chart
Loading chart...
Decelerating Growth Challenges Doximity's Premium Valuation
Investment Thesis • Updated 2026Q4
VerdictNegative
Growth:Decelerating
Profitability:Moderate
Financial:Healthy
Cash Flow:Mixed
Primary Risk:Pharmaceutical marketing budget sensitivity
Key Thesis Takeaways
- Doximity faces a critical inflection point as year-over-year revenue growth decelerated to 5.1% in 2026Q4, signaling potential saturation in its core pharmaceutical marketing niche.
- While the company maintains a robust 86.7% gross margin, the erosion of operating margins to 17.1% and the depletion of retained earnings to a negative $51.1M suggest that aggressive capital allocation strategies may be outpacing organic performance.
- Investors should monitor whether the firm can restore operating leverage and stabilize cash flow volatility, as current valuation multiples appear increasingly disconnected from the cooling growth trajectory.
Verdict Logic
the combination of decelerating revenue growth at 5.1% and the erosion of retained earnings to negative $51.1M suggests that the current valuation is not supported by underlying fundamental momentum.
DOCS Growth Metrics
Doximity, Inc. (DOCS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years25.53%
3 Years15.45%
TTM13.05%
Profit CAGR
10 Years-
5 Years31.32%
3 Years20.23%
TTM-12.16%
EPS CAGR
10 Years-
5 Years52.2%
3 Years22.74%
TTM-10.81%
Return on Capital
10 Years23.62%
5 Years19.08%
3 Years20.01%
Last Year20.7%
DOCS Recent Earnings
Doximity, Inc. (DOCS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 11/12 qtrs (92%)●Beat Revenue 11/12 qtrs (92%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.26-7.1%
$0.28
Rev
$145M+0.9%
$144M
Q1 2026
Feb 5, 2026Metric
Actual
Est
EPS
$0.46+4.5%
$0.44
Rev
$185M+1.9%
$182M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.45+18.8%
$0.38
Rev
$169M+6.7%
$158M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.36+19.4%
$0.30
Rev
$146M+4.6%
$140M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.26vs $0.28-7.1% | $145Mvs $144M+0.9% |
| Q1 2026 | Feb 5, 2026 | $0.46vs $0.44+4.5% | $185Mvs $182M+1.9% |
| Q4 2025 | Nov 6, 2025 | $0.45vs $0.38+18.8% | $169Mvs $158M+6.7% |
| Q3 2025 | Aug 7, 2025 | $0.36vs $0.30+19.4% | $146Mvs $140M+4.6% |
Based on last 12 quarters of dataView full earnings history →
Latest DOCS News
Recent stock market news and headlines for Doximity, Inc. (DOCS)
Zacks Investment Research·Jun 16, 2026
Doximity (DOCS) Advances While Market Declines: Some Information for InvestorsDoximity (DOCS) closed at $20.89 in the latest trading session, marking a +1.02% move from the prior day.
Peers Comparison
Key metrics vs top competitors for Doximity, Inc. (DOCS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $22.86 | $4.28B | 23.33 | 13.05% | 30.4% | 19.28% | — | |
| $38.28 | $8.4B | 75.06 | 59% | -0.56% | -2.48% | — | |
| $232.69 | $163.03B | 167.40 | 35.82% | 12.31% | 3.49% | — | |
| $17.32 | $1.97B | -14.20 | 8.28% | -25.66% | -50.82% | — | |
| $192.01 | $31.19B | 35.30 | 16.34% | 28.37% | 13.36% | — | |
| $21.82 | $1.61B | 6.61 | 18.52% | 118.91% | 47.59% | — |
Compare DOCS vs Peers
Doximity, Inc. (DOCS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
DOCS SEC Filings & Documents
Doximity, Inc. (DOCS) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
Apr 17, 2026·SEC
Material company update
Feb 5, 2026·SEC
10-K Annual Reports
410-Q Quarterly Reports
6Get notified when DOCS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
DOCS Frequently Asked Questions
Doximity, Inc. (DOCS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Doximity, Inc.'s revenue?
Doximity, Inc. (DOCS) reported $644.9M in revenue for fiscal year 2026. This represents a 653% increase from $85.7M in 2019.
How fast is Doximity, Inc. growing?
Doximity, Inc. (DOCS) grew revenue by 13.1% over the past year. This is steady growth.
Is DOCS profitable?
Yes, Doximity, Inc. (DOCS) is profitable, generating $196.1M in net income for fiscal year 2026 (30.4% net margin).
Dividend & Returns
What is DOCS's return on equity?
Doximity, Inc. (DOCS) has a return on equity (ROE) of 19.3%. This is reasonable for most industries.
What is Doximity, Inc.'s free cash flow?
Doximity, Inc. (DOCS) generated $214.6M in free cash flow for fiscal year 2026. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.